RT Journal Article
T1 Eucalyptus Essential Oil Inhibits Cell Infection by SARS-CoV-2 Spike Pseudotyped Lentivirus
A1 Alonso Fernández, Sara
A1 Peláez Prestel, Héctor Fernando
A1 Ras Carmona, Álvaro
A1 Mozas Gutiérrez, Juan
A1 Reyes Manzanas, Raquel
A1 Reche Gallardo, Pedro Antonio
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains a public health concern due to infections with new SARS-CoV-2 variants. Therefore, finding effective preventive and therapeutic treatments against all SARS-CoV-2 variants is of great interest. In this study, we examined the capacity of eucalyptus essential oil (EEO) and eucalyptol (EOL) to prevent SARS-CoV-2 infection, using as a model SARS-CoV-2 Spike pseudotyped lentivirus (SARS-CoV-2 pseudovirus) and 293T cells transfected with human angiotensin-converting enzyme 2 (hACE2-293T cells). First, we determined the cytotoxicity of EEO and EOL using the MTT colorimetric assay, selecting non-cytotoxic concentrations ≤ 0.1% (v/v) for further analysis. Subsequently, we evaluated the capacity of EEO and EOL in cell cultures to preclude infection of hACE2-293T cells by SARS-CoV-2 pseudovirus, using a luciferase-based assay. We found that EEO and EOL significantly reduced SARS-CoV-2 pseudovirus infection, obtaining IC50 values of 0.00895% and 0.0042% (v/v), respectively. Likewise, EEO and EOL also reduced infection by vesicular stomatitis virus (VSV) pseudovirus, although higher concentrations were required. Hence, EEO and EOL may be able to inhibit SARS-CoV-2 infection, at least partially, through a Spike-independent pathway, supporting the implementation of aromatherapy with these agents as a cost-effective antiviral measure.
PB MDPI
SN 2227-9059
YR 2024
FD 2024-08-19
LK https://hdl.handle.net/20.500.14352/131189
UL https://hdl.handle.net/20.500.14352/131189
LA eng
NO Citation: Fernandez, S.A.; Pelaez-Prestel, H.F.; Ras-Carmona, A.; Mozas-Gutierrez, J.; Reyes-Manzanas, R.; Reche, P.A. Eucalyptus Essential Oil Inhibits Cell Infection by SARS-CoV-2 Spike Pseudotyped Lentivirus. Biomedicines 2024, 12, 1885. https://doi.org/10.3390/ biomedicines12081885
NO Comunidad Autónoma de Madrid
DS Docta Complutense
RD 25 feb 2026